New release: nice to see continuing innovation but nicer if it starts showing up in the bottom line!
Ed
------
Laserscope Requests FDA Marketing Clearance for Industry's Most
Compact Erbium Laser System
Business Wire - January 27, 1998 08:21
%LASERSCOPE LSCP %CALIFORNIA %MEDICINE %BIOTECHNOLOGY %PRODUCT V%BW P%BW
Jump to first matched term
Small, Powerful System to be Unveiled At American Academy of Dermatology Convention in Late February
SAN JOSE, Calif.--(BW HealthWire)--Jan. 27, 1998--Laserscope (NASDAQ:LSCP) today announced that it has filed a 510(k) premarket notification with the U.S. Food and Drug Administration for a new, portable, high power Erbium:YAG laser system. The notification to the FDA includes specific laser applications in dermatology, cosmetic and plastic surgery, general surgery, gynecology, ENT and ophthalmology. According to Robert V. McCormick, Laserscope President & CEO, "When approved, the Venus(TM) Laser System will be the smallest, yet among the most powerful, Erbium:YAG lasers on the market for skin resurfacing and other laser procedures.
"Because the Venus system is roughly the same size as our desktop Aura(TM) KTP system, about one-half the size and one-half the weight of most other Erbium systems on the market, we expect it to be well received by physicians performing skin rejuvenation procedures. The features and performance characteristics of the system will meet or exceed those of competitive systems at a price we believe customers will find exceptionally attractive. We expect to begin marketing the system in mid-1998. "Since the Erbium:YAG wavelength is more superficially absorbed by the skin than the CO2 wavelength, it provides a gentler form of skin resurfacing and skin rejuvenation," said Mr. McCormick. "It provides an ideal treatment for younger patients with mild wrinkles or moderate sun damage, and can be used on both facial and non-facial skin such as the hands. Healing time can be up to twice as fast as with conventional CO2 skin resurfacing.
"Venus should prove to be a perfect complement to our Pulsar(TM) CO2 Laser System. We plan to demonstrate the new system at the American Academy of Dermatology annual meeting in Orlando in late February 1998." Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center and hospital markets. The Company is a pioneer in the development and commercialization of lasers and advanced fiberoptic devices for a wide variety of applications, including photoselective medicine to treat cancer and other diseases. Its Ascent Medical Systems(TM) (AMS) provide innovative, custom equipment solutions for surgical suites and medical treatment rooms. More information on Laserscope and its products can be found on the Company's Website at www.laserscope.com Except for the historical information presented, the matters discussed in this announcement contain forward-looking statements that involve risks and uncertainties, including the ability to obtain necessary regulatory approvals on a timely basis, the timely introduction and market acceptance of new products and procedures, the development and rate of growth of new markets and treatments, the impact of competitive products and technologies, physician and consumer acceptance of and demand for the medical procedures targeted by the company, and other risks detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope's most recent Forms 10K and 10Q are available upon request from its Investor Relations Department.
CONTACT: Laserscope
Richard Wood (IR/Media) or
Dennis LaLumandiere (Financial), 408/943-0636
or
Hilary Kaye Associates
Hilary Kaye or Shelle Murach, 714/851-5150 |
